Weekly Analysts’ Ratings Changes for Arvinas (ARVN)

Several analysts have recently updated their ratings and price targets for Arvinas (NASDAQ: ARVN):

• 3/13/2025 – Arvinas was downgraded by analysts at The Goldman Sachs Group, Inc. from a “buy” rating to a “neutral” rating. They now have a $15.00 price target on the stock, down previously from $70.00.
• 3/13/2025 – Arvinas had its price target lowered by analysts at Morgan Stanley from $48.00 to $12.00. They now have an “equal weight” rating on the stock.
• 3/13/2025 – Arvinas had its price target lowered by analysts at Guggenheim from $57.00 to $32.00. They now have a “buy” rating on the stock.
• 3/12/2025 – Arvinas was given a new $20.00 price target on by analysts at BMO Capital Markets. They now have an “outperform” rating on the stock.
• 3/12/2025 – Arvinas was given a new $26.00 price target on by analysts at Wells Fargo & Company. They now have an “overweight” rating on the stock.
• 3/12/2025 – Arvinas was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” rating. They now have a $12.00 price target on the stock, down previously from $57.00.
• 3/12/2025 – Arvinas had its price target lowered by analysts at Bank of America Co. from $54.00 to $28.00. They now have a “buy” rating on the stock.
• 3/11/2025 – Arvinas was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
• 3/11/2025 – Arvinas had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $81.00 price target on the stock.
• 3/7/2025 – Arvinas had its price target lowered by analysts at Citigroup Inc. from $28.00 to $19.00. They now have a “neutral” rating on the stock.
• 2/12/2025 – Arvinas had its price target raised by analysts at Oppenheimer Holdings Inc. from $40.00 to $45.00. They now have an “outperform” rating on the stock.
• 2/12/2025 – Arvinas had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $82.00 price target on the stock, down previously from $88.00.
• 2/12/2025 – Arvinas had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $57.00 price target on the stock.
• 2/12/2025 – Arvinas had its price target lowered by analysts at Stifel Nicolaus from $63.00 to $51.00. They now have a “buy” rating on the stock.
• 2/11/2025 – Arvinas had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
• 2/7/2025 – Arvinas had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 2/3/2025 – Arvinas had its price target lowered by analysts at Barclays PLC from $48.00 to $32.00. They now have an “overweight” rating on the stock.

Arvinas Price Performance

NASDAQ ARVN traded up $0.01 on Thursday, reaching $7.96. 329,899 shares of the company’s stock traded hands, compared to its average volume of 958,288. Arvinas, Inc. has a 12 month low of $7.90 and a 12 month high of $41.98. The stock has a market cap of $547.08 million, a PE ratio of -2.87 and a beta of 1.95. The stock has a 50-day simple moving average of $15.67 and a 200 day simple moving average of $20.91.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the firm earned ($2.53) earnings per share. As a group, analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.

Insider Transactions at Arvinas

In other news, insider Noah Berkowitz sold 8,658 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. This trade represents a 7.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,230 shares of company stock worth $769,402. 5.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arvinas

Several large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Arvinas in the 4th quarter valued at approximately $28,000. KBC Group NV lifted its position in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP grew its holdings in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Arvinas in the fourth quarter worth about $171,000. Finally, Tema Etfs LLC purchased a new stake in Arvinas in the fourth quarter worth about $227,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.